Breaking News Instant updates and real-time market news.

LB

L Brands

$24.29

1.605 (7.08%)

, VIPS

Vipshop

$7.75

0.095 (1.24%)

18:53
05/22/19
05/22
18:53
05/22/19
18:53

Fly Intel: After Hours Movers

UP AFTER EARNINGS: L Brands (LB) up 13.2%... Vipshop (VIPS) up 6.9%... Copart (CPRT) up 3.4%... Ctrip (CTRP) up 2.0%... Synopsys (SNPS) up 0.4%. ALSO HIGHER: Avon Products (AVP) up 15.5% after Natura confirmed it is buying Avon Products... Iovance Biotherapeutics (IOVA) up 7.9% after receiving FDA Breakthrough Therapy designation for LN-145...Gilead (GILD) up 0.9% after being upgraded at Citi to Buy... Amgen (AMGN) up 0.8% after being upgraded at Citi to Buy. DOWN AFTER EARNINGS: NetApp (NTAP) down 6.7%... Shoe Carnival (SCVL) down 2.5%... Huazhu Group (HTHT) down 2.0%... Star Bulk (SBLK) down 1.6%. ALSO LOWER: Organovo (ONVO) down 14.1% after guiding Q4 revenue. Movers as of 18:30ET.

LB

L Brands

$24.29

1.605 (7.08%)

VIPS

Vipshop

$7.75

0.095 (1.24%)

CPRT

Copart

$64.99

-0.91 (-1.38%)

CTRP

Ctrip

$37.78

-0.09 (-0.24%)

SNPS

Synopsys

$115.10

-0.63 (-0.54%)

AVP

Avon Products

$4.07

0.875 (27.39%)

GILD

Gilead

$67.25

0.73 (1.10%)

IOVA

Iovance Biotherapeutics

$17.71

1.5 (9.25%)

AMGN

Amgen

$173.23

3.61 (2.13%)

NTAP

NetApp

$62.58

-7.43 (-10.61%)

SCVL

Shoe Carnival

$29.65

-2.6 (-8.06%)

HTHT

Huazhu Group

$34.41

-0.47 (-1.35%)

SBLK

Star Bulk Carriers

$8.13

-0.13 (-1.57%)

ONVO

Organovo

$0.78

-0.158 (-16.84%)

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 31

    May

  • 03

    Jun

  • 06

    Jun

  • 10

    Jun

  • 10

    Jun

  • 13

    Jun

  • 09

    Jul

  • 16

    Jul

  • 17

    Jul

  • 26

    Sep

  • 27

    Sep

LB L Brands
$24.29

1.605 (7.08%)

04/26/19
ODEN
04/26/19
INITIATION
ODEN
Buy
L Brands initiated with a Buy at Odeon Capital
05/15/19
LOOP
05/15/19
NO CHANGE
Target $20
LOOP
Sell
L Brands price target lowered to $20 from $23 at Loop Capital
Loop Capital analyst Laura Champine lowered her price target on L Brands to $20 and kept her Sell rating ahead of her expected "disappointing" Q1, with zero expected earnings and a 4% decline in stores. The analyst also lowers her FY19 and FY20 EPS view by 19c and 33c to $2.18 and $2.08, noting that the updated product line for Victoria's Secret under new management is not expected until the end of 2019. Champine expects the VS brand continuing to drag on the company's overall results and sees no other short-term catalysts to improve performance at L Brands.
03/20/19
JEFF
03/20/19
NO CHANGE
Target $16
JEFF
Underperform
Jefferies says sell L Brands 'aggressively' after analysis shows elevated promos
Jefferies analyst Randal Konik says his updated analysis of Victoria's Secret and Pink discounts shows elevated promotion levels "that indicate share loss is mounting." Victoria's Secret panty prices are at record lows, bringing back swim is not the answer, and key products are continuing to be promoted, Konik tells investors in a research note. The analyst's estimates for L Brands remain below consensus and he continues to believe Victoria's Secret and Pink will continue to erode while Bath & Body Works "is rolling over." Konik would "sell shares aggressively" and keeps an Underperform rating on L Brands with a $16 price target.
04/01/19
JEFF
04/01/19
NO CHANGE
Target $16
JEFF
Underperform
Pink sales may be cut in half over next 24 months, says Jefferies
Jefferies analyst Randal Konik believes the brand event at Rutgers University shows L Brands' Pink is "lacking energy" and that "brand engagement is waning," which he says is the strongest indicator of brand health. The analyst thinks Pink sales may be cut in half "or more" within the next 12-24 months. This creates further earnings cuts for L Brands so sell the shares, Konik tells investors in a research note titled #PINK Is Canary In Coal Mine As Rutgers PINK Event Shows Brand Over." The analyst keeps an Underperform rating on L Brands with a $16 price target.
VIPS Vipshop
$7.75

0.095 (1.24%)

04/30/19
JPMS
04/30/19
UPGRADE
Target $11
JPMS
Overweight
JPMorgan upgrades Vipshop to Overweight with $11 target on strategic shift
JPMorgan analyst Alex Yao upgraded Vipshop to Overweight from Neutral and raised his price target for the shares to $11 from $6.50. The analyst says he's turning more positive on Vipshop's earnings growth outlook following its strategic shift to move non-core, low-margin or loss-making categories to third parties and potentially transition in-house logistics to an outsourced model. These two changes will lead to structural, as opposed to one-off, changes in Vipshop's cost structure, Yao tells investors in a research note. The analyst thinks the company could achieve a 41% annual earnings growth in the next two years, which eh notes is "far faster than most of the names in our coverage universe and with strong visibility."
04/30/19
JPMS
04/30/19
UPGRADE
JPMS
Overweight
Vipshop upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Alex Yao upgraded Vipshop to Overweight from Neutral saying cost savings can drive "sizable" earnings upside.
04/30/19
04/30/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Alaska Air (ALK) upgraded to Overweight from Neutral at JPMorgan with analyst Jamie Baker saying shares of Alaska Air are a laggard year-to-date, having underperformed the market by nearly 17%. 2. Northrop Grumman (NOC) upgraded to Overweight from Neutral at Alembic Global. 3. JD.com (JD) upgraded to Overweight from Neutral at JPMorgan. 4. Noble Energy (NBL) upgraded to Equal Weight from Underweight at Barclays with analyst Jeanine Wai saying the company's fundamentals have improved. 5. Vipshop (VIPS) upgraded to Overweight from Neutral at JPMorgan with analyst Alex Yao saying he's turning more positive on Vipshop's earnings growth outlook following its strategic shift to move non-core, low-margin or loss-making categories to third parties and potentially transition in-house logistics to an outsourced model. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/22/19
UBSW
04/22/19
DOWNGRADE
UBSW
Sell
Vipshop downgraded to Sell from Neutral at UBS
CPRT Copart
$64.99

-0.91 (-1.38%)

05/17/19
GUGG
05/17/19
DOWNGRADE
GUGG
Neutral
Copart downgraded to Neutral from Buy at Guggenheim
11/23/18
RHCO
11/23/18
NO CHANGE
Target $63
RHCO
Buy
SunTrust sees upside potential for Copart from 'secular tailwinds'
SunTrust analyst Stephanie Benjamin kept her Buy rating and $63 price target on Copart after its in-line Q1 earnings, noting that the top-line was driven by higher than expected Vehicle Sales revenue even though its Auctions revenue was below expectations. The analyst maintains her bullish stance on the company with anticipated benefits coming from "higher accident rates, increased vehicle pricing, and further international expansion". Benjamin also cites Copart's details around the progress of its expansion in Germany, stating that having built a network and marketplace in the country, its volumes should "materially increase going forward".
05/17/19
GUGG
05/17/19
DOWNGRADE
GUGG
Neutral
Guggenheim downgrades Copart to Neutral on expected slower industry growth
As previously reported, Guggenheim analyst Ali Faghri downgraded Copart to Neutral from Buy as he predicts an upcoming significant slowing in industry growth due to declining accident frequency and more gradual increases in total loss frequency. He also noted that the stock's current valuation is 30% above its 5-year average, leaving a less favorable risk/reward.
02/26/19
RHCO
02/26/19
NO CHANGE
Target $67
RHCO
Buy
Copart price target raised to $67 from $63 at SunTrust
SunTrust analyst Stephanie Benjamin raised her price target on Copart to $67 and kept her Buy rating after its strong Q2 results. The analyst notes that the new price target implies a multiple of 19-times forward EBITDA estimates, a premium to its 13- to 17-times 5-year average, with the upside coming from the company's favorable secular tailwinds of a younger vehicle inventory, increased revenue per unit, and continued development of its business in Germany.
CTRP Ctrip
$37.78

-0.09 (-0.24%)

05/06/19
MZHO
05/06/19
UPGRADE
MZHO
Buy
Ctrip upgraded to Buy from Neutral at Mizuho
05/07/19
MZHO
05/07/19
UPGRADE
Target $55
MZHO
Buy
Mizuho upgrades Ctrip to Buy with $55 price target into Q1 results
Mizuho analyst James Lee last night upgraded Ctrip (CTRP) to Buy from Neutral and raised his price target for the shares to $55 from $35 ahead of the company's Q1 results. The analyst expects decreased competition along with an improved macro environment and yuan appreciation will drive both domestic and outbound travel. As such, he raised his three-year annual EBITDA growth estimate for Ctrip to 35% from 23% on improved long-term fundamentals. Alibaba (BABA) remains Lee's top pick in the China Internet space.
04/15/19
DBAB
04/15/19
NO CHANGE
DBAB
Ctrip added as catalyst call Buy at Deutsche Bank
05/03/19
MACQ
05/03/19
DOWNGRADE
MACQ
Neutral
Ctrip downgraded to Neutral from Outperform at Macquarie
SNPS Synopsys
$115.10

-0.63 (-0.54%)

05/14/19
WELS
05/14/19
INITIATION
Target $150
WELS
Outperform
Synopsys initiated with an Outperform at Wells Fargo
Wells Fargo analyst Gary Mobley started Synopsys with an Outperform rating and $150 price target. The company offers a "secure, defensible way" to invest in the long-term growth of the semiconductor and electronics systems industries, Mobley tells investors in a research note. The analyst likes the competitive dynamics in the electronic design automation market.
04/10/19
KEYB
04/10/19
INITIATION
Target $135
KEYB
Overweight
Synopsys resumed with an Overweight at KeyBanc
KeyBanc analyst Jason Celino resumed coverage of Synopsys with an Overweight rating and $135 price target. The analyst cited its EDA tailwinds, potential margin leverage, and underappreciated software integrity business. The analyst believes the company could be on a $4B run rate exiting 2021, and with 28% operating margins and a 16% tax rate, he could see over $6.15 in EPS.
05/14/19
WELS
05/14/19
INITIATION
WELS
Outperform
Synopsys initiated with an Outperform at Wells Fargo
04/11/19
RBCM
04/11/19
NO CHANGE
Target $140
RBCM
Top Pick
Synopsys price target raised to $140 from $130 at RBC Capital
RBC Capital analyst Mitch Steves raised his price target for Synopsys to $140 from $130 as upside case increases. After taking a more detailed look through the Synopsys Analyst Day deck, the analyst thinks the upside case for the company now stands at $6.50 EPS and that the stock could be worth about $175 in a more bullish scenario. Additionally, he has increased conviction in margin expansion due to the rising costs of SoC design, and thinks the software integrity business will remain profitable. The analyst reiterates a Top Pick rating on the shares.
AVP Avon Products
$4.07

0.875 (27.39%)

05/10/19
SBSH
05/10/19
NO CHANGE
SBSH
Natura paying 50% premium for Avon 'not the base case,' says Citi
Citi analyst Tobias Stingelin noted that Spanish website Intereconomia.com reported, citing a source, that Santander's board has approved a loan of up to $2.1B for Natura, which he notes has already publicly announced that it is engaged in talks to buy Avon. An all cash transaction of $2.1B, or a 50% premium, is unlikely in his view and he does not believe that this is the base case, Stingelin tells investors. He believes that if a transaction were to take place for Avon it would be at a lower premium and noted that Intereconomia's source said a deal could still be for a combination of cash and stock. Stingelin has a Neutral rating on Natura shares. In afternoon trading, Avon shares are up nearly 10% to $3.18.
09/24/18
DADA
09/24/18
UPGRADE
Target $3.5
DADA
Buy
Avon Products upgraded to Buy at DA Davidson on operational focus of new CEO
As reported earlier, DA Davidson analyst Linda Bolton Weiser upgraded Avon Products (AVP) to Buy from Hold and raised her price target to $3.50 from $1.75. The analyst cites the increased "sense of urgency" under the new CEO Jan Zijderveld displayed in his first analyst meeting, demonstrating his greater engagement in the company's operations, hiring of executives with sales experience, and "establishing a culture of accountability". Based on her increased confidence in Avon's management team, Weiser also raised her target enterprise value to expected FY20 EBITDA target multiple to 6.5-times from 4.5-times, which is still a discount to other direct sellers like Nu Skin (NUS) and Herablife (HLF) trading at 11- to 12-times
09/24/18
09/24/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Plains All American (PAA) and Plains GP Holdings (PAGP) were upgraded to Buy from Hold at Stifel. 2. Avon Products (AVP) upgraded to Buy from Neutral at DA Davidson with analyst Linda Bolton Weiser citing the increased "sense of urgency" under the new CEO Jan Zijderveld displayed in his first analyst meeting, demonstrating his greater engagement in the company's operations, hiring of executives with sales experience, and "establishing a culture of accountability." 3. United Natural Foods (UNFI) upgraded to Sector Perform at RBC Capital with analyst William Kirk saying while core business challenges for the company remain and the risk of the Supervalu acquisition integration continues, its 6.4-times earnings valuation likely accounts for these issues. 4. KVH Industries (KVHI) upgraded to Buy from Neutral at Chardan with analyst James McIlree saying he expects "continued strong growth" from its Agile Plans that should result in improved margins and increased financial predictability. 5. RELX (RELX) upgraded to Overweight from Equal Weight at Barclays with analyst Nick Dempsey saying he views the current valuation as attractive. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/25/19
DADA
03/25/19
NO CHANGE
Target $3.5
DADA
Buy
Avon Products buyout could be valued as high as $4.50/shr, says DA Davidson
DA Davidson analyst Linda Bolton Weiser kept her Buy rating and $3.50 price target on Avon Products after the latest speculation about its potential acquisition by Natura. The analyst believes that the takeout valuation could come at $3.80-$4.50 per share, but intends to assess the Brazil anti-trust rules while also noting Natura's already "leveraged balance sheet, with over $2B of debt and debt-to-EBITDA of 4.3-times".
GILD Gilead
$67.25

0.73 (1.10%)

05/22/19
SBSH
05/22/19
UPGRADE
SBSH
Buy
Gilead upgraded to Buy from Neutral at Citi
05/20/19
FBCO
05/20/19
INITIATION
Target $70
FBCO
Neutral
Gilead initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Gilead Sciences with a Neutral rating and $70 price target. The does not see "outsized growth" in the company's base HIV business that would drive significant upside to earnings projections. He admits, however, that a new strategic vision or acquisition could lead to multiplier expansion.
05/22/19
05/22/19
UPGRADE

Citi assumes coverage of large-cap biotech, upgrades Amgen and Gilead
Citi analyst Mohit Bansal assumed coverage of large-cap biotech stocks, assuming coverage with five Buy ratings -- Amgen (AMGN), Alexion Pharmaceuticals (ALXN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), and BioMarin Pharmaceutical (BMRN) -- and two Neutral ratings -- Biogen (BIIB) and Regeneron Pharmaceuticals (REGN). Both Amgen and Gilead were upgraded to Buy from Neutral as part of the assumption of coverage. The analyst said he is "more optimistic" on the sector as a whole as he sees many biotechs going "back to basics" by investing in their internal pipelines and filling their pipelines with early stage assets. He suggests looking at large caps again, as many are returning to stability and growth. Bansal does not favor large M&A, suggesting discipline due to "realizing value with big M&As."
05/13/19
JEFF
05/13/19
NO CHANGE
Target $95
JEFF
Buy
Gilead shares reflect 'undue bearish outlook,' says Jefferies
Gilead Sciences (GILD) is trading at a 10 times price-to-earnings multiple, which reflects an "undue bearish outlook," Jefferies analyst Michael Yee tells investors in a research note. He thinks the company's base HIV business growing to 2025 and then eroding is worth $60-$65 per share, and the rest of business -- HCV, filgotinib, Yescarta -- is worth $15-$20 per share. This implies the stock should be at $80-$85, says Yee. A bear case on the HIV business is $35-$40 per share, which assumes a full cliff post 2025 or GlaxoSmithKline (GSK) taking "massive" share with doublets and long-acting, adds the analyst. Yee keeps a Buy rating on Gilead with a $95 price target.
IOVA Iovance Biotherapeutics
$17.71

1.5 (9.25%)

05/16/19
JEFF
05/16/19
NO CHANGE
Target $29
JEFF
Buy
Jefferies calls Iovance 'big winner' at ASCO, sees up to 40% share rally
Jefferies analyst Biren Amin calls the data reported by Iovance Biotherapeutics (IOVA) the "big winner" for the American Society of Clinical Oncology annual meeting. The ASCO update suggests Iovance's tumor infiltrating lymphocytes therapy could open the door for cell therapy in the "lucrative" solid-tumor market, Amin tells investors in a research note. He points out the company reported that no new patients have progressed in the melanoma trial and offered first evidence of clinically meaningful durability for TIL therapy. Also, its cervical data that reported a 44% overall response rate is three-times greater than reported with Merck's (MRK) Keytruda in a similar patient population, contends Amin. He believes last night's update could drive a 30%-40% rally in shares of Iovance. The analyst keeps a Buy rating on the name with a $29 price target. Iovance in premarket trading is up 26%, or $2.97, to $14.20.
05/07/19
PIPR
05/07/19
NO CHANGE
Target $20
PIPR
Overweight
Iovance Biotherapeutics well positioned in T-cell therapy, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro kept his Overweight rating and $20 price target on Iovance Biotherapeutics after its Q1 results also disclosed that 3 of its abstracts submitted to ASCO have been accepted. The analyst believes that the company's lifileucel in melanoma update has a "clear opportunity to improve", whiles its LN-145 in cervical cancer data set could be supportive of an accelerated development path. Catanzaro sees Iovance Biotherapeutics as a "best-positioned T-cell therapy" stock, with $440M in cash on hand being sufficient to fund its operations into 2022.
05/16/19
BARD
05/16/19
NO CHANGE
Target $34
BARD
Outperform
Iovance Biotherapeutics price target raised to $34 from $29 at Baird
Baird analyst Madhu Kumar raised his price target for Iovance Biotherapeutics to $34 from $29 and maintained an Outperform rating, citing increased tumor-infiltrading lymphocyte technology conviction on ASCO abstracts in cervical cancer and metastatic melanoma. The abstracts for Phase 2 data for TIL technology increases his conviction in Iova's TILs, particularly in cervical cancer, the analyst says in a research note.
04/29/19
04/29/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Iovance Biotherapeutics (IOVA) initiated with an Overweight at Piper Jaffray. 2. Tradeweb Markets (TW) initiated with a Market Perform at Wells Fargo, a Hold at Jefferies and Sandler O'Neill, an Equal Weight at Morgan Stanley and Barclays, as well as a Neutral at BofA/Merrill, Goldman Sachs, Credit Suisse, and Citi. 3. Penn Virginia (PVAC) initiated with an Outperform at Imperial Capital. 4. NGM Biopharmaceuticals (NGM) initiated with an Outperform at Cowen as well as a Buy at Goldman Sachs and Citi. 5. Silk Road Medical (SILK) initiated with an Overweight at JPMorgan, an Outperform at BMO Capital, a Buy at Stifel, and a Neutral at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
AMGN Amgen
$173.23

3.61 (2.13%)

05/16/19
COWN
05/16/19
NO CHANGE
COWN
Outperform
Amgen early data for AMG 510 'looks strong,' says Cowen
Cowen analyst Yaron Werber said the initial data in ASCO abstract for Amgen's AMG 510 "looks strong" in lung cancer patients and was better than he anticipated. The data, while still early, suggest AMG 510 is a promising therapy for a "sizable" $2B-$2.5B market, Werber tells investors. He maintains an Outperform rating on Amgen shares.
05/20/19
FBCO
05/20/19
INITIATION
Target $208
FBCO
Outperform
Amgen initiated with an Outperform at Credit Suisse
Credit Suisse analyst Evan Seigerman initiated Amgen with an Outperform rating and a price target of $208, saying the stock is "attractive" relative to its peers because of its "underappreciated" biosimilars assets that may offset the expected revenue decline in its core business. The analyst is also positive on Amgen's promising pipeline that includes oncology and immunology assets along with its discounted valuation, noting that the stock is currently trading at 12.1-times expected forward earnings vs. 17.7-times for the S&P500 and 14.4-times or more for its major pharma peers.
05/22/19
SBSH
05/22/19
UPGRADE
SBSH
Buy
Amgen upgraded to Buy from Neutral at Citi
NTAP NetApp
$62.58

-7.43 (-10.61%)

04/11/19
FBCO
04/11/19
INITIATION
Target $89
FBCO
Outperform
NetApp initiated with an Outperform at Credit Suisse
Credit Suisse analyst Matt Cabral initiated NetApp (NTAP) with an Outperform rating and a price target of $89. The analyst cites the company's relative advantage in a "push toward hybrid" with its "cohesive all-flash business and Data Fabric strategy" and expects its market share to grow to 14% from 12%. Cabral also notes NetApp's rebound in product sales as a leading indicator for services, anticipating services revenue growth to accelerate to 2% in FY20 and 5% in FY21 from 1% in FY19. The analyst adds that NetApp has gross margin upside from the higher margins in Product and improved sales mix in Services segments.
02/14/19
02/14/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exxon Mobil (XOM) double upgraded to Outperform from Underperform at Macquarie with analyst David Hewitt saying with a "world class" Guyana play, multiple liquefied natural gas developments, the Permian "juggernaut" and growth in the integrated downstream, Exxon is "well positioned for the future, and is not being overly distracted by the energy transition debate." 2. Synchrony (SYF) upgraded to Buy from Neutral at Goldman Sachs with analyst Ryan Nash saying with shares trading at a discount to peers due to credit-related concerns, the current valuation is "compelling." 3. Teva (TEVA) upgraded to Outperform from Market Perform at Raymond James. 4. Elevate Credit (ELVT) upgraded to Buy from Neutral at BTIG with analyst Mark Palmer saying he views the shares as "simply too inexpensive" at current levels. 5. NetApp (NTAP) upgraded to Buy from Hold at Cross Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/29/19
PIPR
03/29/19
NO CHANGE
PIPR
Piper updates coverage rankings in Security, Storage and Networking
Piper Jaffray analyst Andrew Nowinski updated his rankings across his coverage universe, which includes the Security, Storage and Networking segments. The analyst's top picks in Security are Okta (OKTA), Palo Alto Networks (PANW) and SailPoint (SAIL). His top picks in Storage are Nutanix (NTNX) and NetApp (NTAP). And his top Networking picks are Akamai (AKAM) and Arista Networks (ANET).
05/17/19
PIPR
05/17/19
NO CHANGE
Target $81
PIPR
Overweight
NetApp price target lowered to $81 from $90 at Piper Jaffray
Piper Jaffray analyst Andrew Nowinski lowered his price target for NetApp to $81 from $90 to reflect his reduced growth assumptions. The analyst now expects revenue growth of 3.2% in fiscal 2020 and 4.8% in fiscal 2021. Nowinski notes that results for NetApp declined in his firm's April reseller survey with only 15% of resellers "above plan." This marked the second consecutive quarter that results have declined and also marked the lowest level since Q1 of 2016, Nowinski tells investors in a research note. The analyst, however, reiterates an Overweight rating on NetApp shares.
SCVL Shoe Carnival
$29.65

-2.6 (-8.06%)

01/02/19
SUSQ
01/02/19
UPGRADE
Target $42
SUSQ
Positive
Shoe Carnival upgraded to Positive at Susquehanna
As reported previously, Susquehanna analyst Sam Poser upgraded Shoe Carnival to Positive from Neutral. The analyst noted its strong Q3 results and improvements in customer engagement and merchandising. He believes its momentum will continue with more targeted customer communications and the correct level of more relevant assortments. Poser has a $42 price target on Shoe Carnival shares.
01/02/19
01/02/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bausch Health (BHC) upgraded to Overweight from Neutral at Piper Jaffray with analyst David Amsellem saying while he's been "unrelentingly negative" on the company for years, it is time to "turn the page following a closer look at the business." 2. Crocs (CROX) and Shoe Carnival (SCVL) were upgraded to Positive from Neutral at Susquehanna. 3. Stryker (SYK) upgraded to Outperform from In Line at Evercore ISI. 4. CBS (CBS) upgraded to Overweight from Equal Weight at Stephens with analyst Kyle Evans saying he believes investor sentiment is poised to improve on the name in 2019 and that the company can continue to post solid results driven by underlying unit growth and stronger pricing. 5. Sirius XM (SIRI) upgraded to Overweight from Neutral at JPMorgan with analyst Sebastiano Petti saying Sirius XM shares are attractively following the 25% pullback from the 2018 highs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/02/19
SUSQ
01/02/19
UPGRADE
SUSQ
Positive
Shoe Carnival upgraded to Positive from Neutral at Susquehanna
04/05/19
SIDC
04/05/19
UPGRADE
Target $42
SIDC
Buy
Shoe Carnival upgraded to Buy on valuation at Sidoti
Sidoti analyst Gregory Pendy upgraded Shoe Carnival to Buy from Neutral citing valuation and maintained a $42 price target.
HTHT Huazhu Group
$34.41

-0.47 (-1.35%)

04/30/19
JPMS
04/30/19
DOWNGRADE
JPMS
Neutral
Huazhu Group downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Leon Chik downgraded Huazhu Group to Neutral from Overweight citing the company's growth slowdown in Q1.
03/17/19
MSCO
03/17/19
DOWNGRADE
MSCO
Underweight
Huazhu Group downgraded to Underweight from Equal Weight at Morgan Stanley
05/06/19
DAIW
05/06/19
DOWNGRADE
DAIW
Underperform
Huazhu Group downgraded to Underperform from Outperform at Daiwa
05/06/19
CHRS
05/06/19
DOWNGRADE
CHRS
Hold
Huazhu Group downgraded to Hold from Buy at China Renaissance
SBLK Star Bulk Carriers
$8.13

-0.13 (-1.57%)

01/04/19
DNBM
01/04/19
INITIATION
DNBM
Buy
Star Bulk Carriers initiated with a Buy at DNB Markets
02/15/19
MSCO
02/15/19
DOWNGRADE
MSCO
Equal Weight
Star Bulk Carriers downgraded to Equal Weight from Overweight at Morgan Stanley
02/15/19
MSCO
02/15/19
DOWNGRADE
Target $9.5
MSCO
Equal Weight
Star Bulk Carriers downgraded to Equal Weight at Morgan Stanley
As previously reported, Morgan Stanley analyst Fotis Giannakoulis downgraded Star Bulk Carriers to Equal Weight from Overweight as he believes the dry bulk shipping market has entered into a period of structural slowdown given that both iron ore and coal are not currently growing. Despite his "guarded" long-term outlook for seaborne bulk trade, Giannakoulis believes the risk/reward in the stock is balanced as he thinks current valuation already discounts market weakness, he added. He lowered his price target on Star Bulk Carriers shares to $9.50 from $15, noting that he anticipates a drop in ship prices.
11/08/18
DBAB
11/08/18
NO CHANGE
Target $17
DBAB
Buy
Star Bulk Carriers recent selloff a buying opportunity, says Deutsche Bank
Deutsche Bank analyst Amit Mehrotra attributes the recent 20% pullback in shares of Star Bulk Carriers to technical pressure from a large institutional investor exiting its position as well as near-term weakness in dry bulk spot rates following a derailment at a BHP iron ore export facility in Australia. Both of these issues are transitory, says Mehrotra, who points out that BHP noted today that it expects partial rail operations to resume in "about one week". The analyst believes Star Bulk continues to be well positioned for a "much higher" equity value and estimates the shares are trading at a 30% discount to net asset value. Mehrotra keeps a Buy rating on Star Bulk Carriers with a $17 price target. He views the recent selloff as a buying opportunity.
ONVO Organovo
$0.78

-0.158 (-16.84%)

12/13/18
HCWC
12/13/18
INITIATION
Target $2.5
HCWC
Buy
Organovo initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce started Organovo Holdings with a Buy rating and $2.50 price target. Though early, the therapeutic tissue opportunity is compelling, Arce tells investors in a research note. The analyst views Organovo as the "clear leader in the early, pioneering technology of 3D bioprinting of solid organs."

TODAY'S FREE FLY STORIES

AGLNF

AGL Energy

$0.00

(0.00%)

19:28
06/17/19
06/17
19:28
06/17/19
19:28
Upgrade
AGL Energy rating change  »

AGL Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPWR

SunPower

$8.27

0.03 (0.36%)

, RUN

Sunrun

$17.09

0.64 (3.89%)

19:02
06/17/19
06/17
19:02
06/17/19
19:02
Upgrade
SunPower, Sunrun, SolarEdge rating change  »

SunPower, Sunrun upgraded…

SPWR

SunPower

$8.27

0.03 (0.36%)

RUN

Sunrun

$17.09

0.64 (3.89%)

SEDG

SolarEdge

$56.58

0.09 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGI

MoneyGram

$1.44

-0.06 (-4.00%)

, PHAS

PhaseBio

$12.25

0.74 (6.43%)

18:48
06/17/19
06/17
18:48
06/17/19
18:48
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: MoneyGram (MGI)…

MGI

MoneyGram

$1.44

-0.06 (-4.00%)

PHAS

PhaseBio

$12.25

0.74 (6.43%)

SPWR

SunPower

$8.27

0.03 (0.36%)

RUN

Sunrun

$17.09

0.64 (3.89%)

STLD

Steel Dynamics

$26.23

-0.19 (-0.72%)

BHVN

Biohaven Pharmaceutical

$57.33

-5.63 (-8.94%)

RMTI

Rockwell Medical

$4.39

0.2 (4.77%)

CALA

Calithera Biosciences

$5.87

0.64 (12.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 18

    Jun

  • 19

    Jun

AAPL

Apple

$193.90

1.06 (0.55%)

18:44
06/17/19
06/17
18:44
06/17/19
18:44
Periodicals
Apple's tvOS 13 beta 2 includes Picture-in-Picture support, 9to5Mac reports »

Apple's tvOS 13 beta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEDG

SolarEdge

18:33
06/17/19
06/17
18:33
06/17/19
18:33
Upgrade
SolarEdge rating change at Goldman Sachs »

SolarEdge upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RUN

Sunrun

$17.09

0.64 (3.89%)

18:33
06/17/19
06/17
18:33
06/17/19
18:33
Upgrade
Sunrun rating change at Goldman Sachs »

Sunrun upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPWR

SunPower

$8.27

0.03 (0.36%)

18:33
06/17/19
06/17
18:33
06/17/19
18:33
Upgrade
SunPower rating change at Goldman Sachs »

SunPower upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLSFY

Bluescope Steel

$0.00

(0.00%)

18:32
06/17/19
06/17
18:32
06/17/19
18:32
Hot Stocks
Bluescope Steel cuts FY19 EBIT growth view to up 6% from up 10% »

BlueScope announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFF

International Flavors

$147.54

-1.25 (-0.84%)

18:24
06/17/19
06/17
18:24
06/17/19
18:24
Hot Stocks
International Flavors CEO: We have planned for Brexit and China is benign for us »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$57.63

-0.65 (-1.12%)

18:24
06/17/19
06/17
18:24
06/17/19
18:24
Periodicals
Senator aims to bar Huawei from seeking damages in patent courts, Reuters says »

U.S. Senator Marco Rubio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 20

    Jun

  • 26

    Jun

  • 27

    Jun

  • 09

    Jul

  • 01

    Aug

BHVN

Biohaven Pharmaceutical

$57.33

-5.63 (-8.94%)

18:12
06/17/19
06/17
18:12
06/17/19
18:12
Hot Stocks
Breaking Hot Stocks news story on Biohaven Pharmaceutical »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$39.00

1.46 (3.89%)

18:04
06/17/19
06/17
18:04
06/17/19
18:04
Hot Stocks
Dish launches OnTech Smart Services »

Dish announced the launch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$32.30

-0.06 (-0.19%)

18:03
06/17/19
06/17
18:03
06/17/19
18:03
Hot Stocks
AT&T wins 24 GHz spectrum following FCC Auction 102 »

AT&T is the winning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

BHVN

Biohaven Pharmaceutical

$57.33

-5.63 (-8.94%)

18:02
06/17/19
06/17
18:02
06/17/19
18:02
Syndicate
Biohaven Pharmaceutical offers to sell $300M in common stock »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSM

Versum Materials

$51.42

0.01 (0.02%)

, MKGAY

Merck KGaA

$0.00

(0.00%)

18:01
06/17/19
06/17
18:01
06/17/19
18:01
Hot Stocks
Versum Materials shareholders approve merger with Merck KGaA »

Versum Materials (VSM)…

VSM

Versum Materials

$51.42

0.01 (0.02%)

MKGAY

Merck KGaA

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

VLO

Valero

$76.93

0.19 (0.25%)

18:00
06/17/19
06/17
18:00
06/17/19
18:00
Periodicals
Valero restarting Port Arthur, Texas refinery hydrocracker, Reuters says »

Valero is restarting the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

VLO

Valero

$76.93

0.19 (0.25%)

17:59
06/17/19
06/17
17:59
06/17/19
17:59
Periodicals
Valero restarting Meraux, Louisiana refinery hydrocracker, Reuters says »

Valero is restarting the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

MGI

MoneyGram

$1.44

-0.06 (-4.00%)

17:44
06/17/19
06/17
17:44
06/17/19
17:44
Hot Stocks
MoneyGram spikes almost 140% after blockchain company Ripple investment »

Money transfer company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

JKS

JinkoSolar

$22.59

-2.08 (-8.43%)

17:37
06/17/19
06/17
17:37
06/17/19
17:37
Downgrade
JinkoSolar rating change  »

JinkoSolar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

FCEL

FuelCell

$0.33

-0.0231 (-6.56%)

17:26
06/17/19
06/17
17:26
06/17/19
17:26
Earnings
FuelCell reports Q2 ($2.06), consensus ($2.24) »

Reports Q2 revenue $9.2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMTI

Rockwell Medical

$4.39

0.2 (4.77%)

17:25
06/17/19
06/17
17:25
06/17/19
17:25
Hot Stocks
Breaking Hot Stocks news story on Rockwell Medical »

Rockwell Medical down 21%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

VRS

Verso

$17.91

-0.24 (-1.32%)

17:21
06/17/19
06/17
17:21
06/17/19
17:21
Hot Stocks
Verso adopts limited duration stockholder rights plan »

Verso announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHVKF

China Vanke Co

$0.00

(0.00%)

17:19
06/17/19
06/17
17:19
06/17/19
17:19
Downgrade
China Vanke Co rating change at Morgan Stanley »

China Vanke Co downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCKT

Rocket Pharmaceuticals

$16.88

0.68 (4.20%)

17:17
06/17/19
06/17
17:17
06/17/19
17:17
Syndicate
Breaking Syndicate news story on Rocket Pharmaceuticals »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

BA

Boeing

$354.90

7.71 (2.22%)

, EADSY

Airbus

$0.00

(0.00%)

17:17
06/17/19
06/17
17:17
06/17/19
17:17
Periodicals
Boeing gets zero new plane orders at Paris Air Show so far, CNBC says »

According to CNBC's…

BA

Boeing

$354.90

7.71 (2.22%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.